Ethanol Induces Skeletal Muscle Autophagy

Status Recruiting

Clinical Trial Summary

In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.

Clinical Trial Description

Hypothesis: Ethanol mediated modification of skeletal muscle proteins to form MAA adducts that in turn induce skeletal muscle autophagy. Patients with alcoholic steatosis, hepatitis and cirrhosis (n=10 each) will be recruited from the liver transplant nutrition clinic or the hepatology inpatient service and their body composition quantified using anthropometry, bioelectrical impedance analysis, CT image analysis and DEXA if available. Control Subjects. Controls will be recruited by advertisement. All control subjects will have a normal clinical history, physical examination, and screening chemistries. They will not have any significant medical conditions requiring the use of medications. Their nutritional status within 20% of normal as defined by ideal body weight. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03209791
Study type	Observational
Source	The Cleveland Clinic
Contact	Revathi Penumatsa, MPH
Phone	2164450688
Email	penumar@ccf.org
Status	Recruiting
Phase
Start date	May 18, 2015
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00708617` - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease	N/A
Completed	`NCT00990639` - Effect of Candesartan in Alcoholic Liver Fibrosis	Phase 1/Phase 2
Recruiting	`NCT04106518` - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting	`NCT04666402` - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting	`NCT02331745` - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure	Phase 4
Completed	`NCT01501162` - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease	Phase 4
Recruiting	`NCT05895890` - French National MICMAF Cohort
Completed	`NCT04557774` - Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Recruiting	`NCT03267069` - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting	`NCT03295812` - Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)	N/A
Recruiting	`NCT05855031` - The Liver Care Trial	N/A
Not yet recruiting	`NCT03503708` - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease	N/A
Completed	`NCT02796469` - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis	N/A
Completed	`NCT02140294` - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease	N/A
Recruiting	`NCT04736966` - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease	Phase 1
Recruiting	`NCT04400604` - Study of Alcohol-related Liver Disease in Europe
Completed	`NCT03402256` - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients	N/A
Completed	`NCT01711125` - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease	Phase 3
Active, not recruiting	`NCT03863730` - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota	N/A
Not yet recruiting	`NCT06307964` - Intra-Hepatic Microbiota in Alcoholic Hepatitis